Business Context and Reporting Period
Company: Evotec SE
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Evotec is a life science company providing drug discovery, preclinical development, and manufacturing services. The company operates through two primary segments: Discovery & Preclinical Development (D&PD) and Just – Evotec Biologics (JEB). In 2025, the company executed a strategic shift toward an "asset-lighter" model, highlighted by the sale of its Just – Evotec Biologics EU SAS subsidiary in Toulouse to Sandoz AG.
Key Financial Metrics
| Metric | 2025 (€ millions) | 2024 (€ millions) | Variance |
|---|---|---|---|
| Revenue | 788.4 | 797.0 | (1.1)% |
| Net Loss | (103.5) | (196.1) | Improvement of €92.6m |
| Adjusted EBITDA | 41.1 | 22.6 | +82.0% |
| Gross Margin | 14.5% | 14.4% | +0.1 pp |
| Cash & Cash Equivalents | 418.5 | 306.4 | +36.6% |
| Total Debt (Loans) | 276.4 | 287.6 | (3.9)% |
| Capital Expenditure | (72.5) | (117.5) | Reduced by €45.0m |
Material Changes vs. Prior Period
- Strategic Divestiture: Completed the sale of Just – Evotec Biologics EU SAS (Toulouse) to Sandoz AG in December 2025. The transaction generated approximately €222.6 million in net cash proceeds and included upfront technology license fees of USD 108 million recognized in revenue.
- Segment Performance:
- D&PD Segment: Revenue decreased 13% to €528.9 million due to lower fee-for-service volumes and unfavorable FX rates. Operating loss improved significantly to €(74.5) million from €(126.2) million, primarily due to the absence of €54.9 million in one-time reorganization costs incurred in 2024.
- JEB Segment: Revenue increased 40% to €259.4 million, driven by the Sandoz partnership and licensing revenue. The segment turned profitable with an operating income of €18.3 million.
- Cost Structure: R&D expenses decreased 26% to €37.5 million due to strategic prioritization. Selling, General, and Administrative (SG&A) expenses decreased 6.5% to €176.0 million.
- Investment Portfolio: Recognized a gain of €12.1 million from the sale of Dark Blue Therapeutics Ltd. and received €7.5 million in insurance reimbursements related to the 2023 cyber-attack.
Guidance, Outlook, and Risks
- Transformation Strategy ("Project Horizon"): Announced in March 2026, this initiative aims to streamline the global footprint from 14 to 10 sites and reduce headcount by up to 800 positions. Management projects cash restructuring costs of approximately €100 million over 2026–2028, with initial savings expected in 2026.
- Liquidity: The company holds €476.4 million in cash, cash equivalents, and investments. The €250 million senior secured revolving credit facility was terminated in June 2025. Management believes current liquidity is adequate for operating plans but may seek incremental funding for strategic initiatives.
- Internal Control Weaknesses: Management identified material weaknesses in internal control over financial reporting as of December 31, 2025. These relate to ineffective risk assessment, IT system access management, and controls over revenue recognition and manual journal entries. An adverse opinion was issued by the auditor regarding internal controls.
- Risks: Key risks include the execution of the new strategy, dependency on key customers (top 10 customers accounted for 61% of revenue), geopolitical instability affecting supply chains, and the potential for future cybersecurity incidents following the 2023 ransomware attack.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of the remediation plan for the identified material weaknesses in internal controls over financial reporting.
- Restructuring Execution: Monitor the execution of "Project Horizon," specifically the timeline for site closures, workforce reductions, and the realization of the projected €75 million in run-rate savings by 2027.
- Customer Concentration: Assess the stability of relationships with top customers, particularly Sandoz and Bristol Myers Squibb, which collectively represent a significant portion of revenue.
- Debt Maturity: Review the maturity profile of outstanding loans (€276.4 million), noting significant repayments due in 2026, and confirm the company's ability to service debt without a revolving credit facility.
- Cybersecurity Posture: Evaluate the effectiveness of new IT security measures implemented following the 2023 ransomware incident and the status of ongoing recovery costs.